Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review

Overview

Journal Front Bioeng Biotechnol

Date 2021 Dec 6

PMID 34869294

Citations 6

Authors

Zeng Zeng

Chao Fang

Ying Zhang

Cong-Xian Chen

Yi-Feng Zhang

Kun Zhang

Affiliations

Soon will be listed here.

Abstract

Mitochondria are the primary organelles which can produce adenosine triphosphate (ATP). They play vital roles in maintaining normal functions. They also regulated apoptotic pathways of cancer cells. Given that, designing therapeutic agents that precisely target mitochondria is of great importance for cancer treatment. Nanocarriers can combine the mitochondria with other therapeutic modalities in cancer treatment, thus showing great potential to cancer therapy in the past few years. Herein, we summarized lipophilic cation- and peptide-based nanosystems for mitochondria targeting. This review described how mitochondria-targeted nanocarriers promoted highly efficient cancer treatment in photodynamic therapy (PDT), chemotherapy, combined immunotherapy, and sonodynamic therapy (SDT). We further discussed mitochondria-targeted nanocarriers' major challenges and future prospects in clinical cancer treatment.

Citing Articles

Nanoengineered mitochondria enable ocular mitochondrial disease therapy the replacement of dysfunctional mitochondria.

Wang Y, Liu N, Hu L, Yang J, Han M, Zhou T Acta Pharm Sin B. 2025; 14(12):5435-5450.

PMID: 39807326 PMC: 11725173. DOI: 10.1016/j.apsb.2024.08.007.

Advancements in mitochondrial-targeted nanotherapeutics: overcoming biological obstacles and optimizing drug delivery.

Li Y, Li X, Wei L, Ye J Front Immunol. 2024; 15:1451989.

PMID: 39483479 PMC: 11524880. DOI: 10.3389/fimmu.2024.1451989.

Current status and trend of mitochondrial research in lung cancer: A bibliometric and visualization analysis.

Kong Q, Zhu Q, Yang Y, Wang W, Qian J, Chen Y Heliyon. 2024; 10(15):e34442.

PMID: 39144972 PMC: 11320136. DOI: 10.1016/j.heliyon.2024.e34442.

Investigation of the Nanoparticulation Method and Cell-Killing Effect following the Mitochondrial Delivery of Hydrophobic Porphyrin-Based Photosensitizers.

Naganawa R, Zhao H, Takano Y, Maeki M, Tokeshi M, Harashima H Int J Mol Sci. 2024; 25(8).

PMID: 38673875 PMC: 11050504. DOI: 10.3390/ijms25084294.

DA7R: A 7-Letter Zip Code to Target PDAC.

Parrasia S, Rossa A, Roncaglia N, Mattarei A, Honisch C, Szabo I Pharmaceutics. 2023; 15(5).

PMID: 37242749 PMC: 10221132. DOI: 10.3390/pharmaceutics15051508.

References

Babu P, Manu P, Dhanya T, Tapas P, Meera R, Surendran A . Bis(3,5-diiodo-2,4,6-trihydroxyphenyl)squaraine photodynamic therapy disrupts redox homeostasis and induce mitochondria-mediated apoptosis in human breast cancer cells. Sci Rep. 2017; 7:42126. PMC: 5294812. DOI: 10.1038/srep42126. View

Dong L, Neuzil J . Mitochondria in cancer: why mitochondria are a good target for cancer therapy. Prog Mol Biol Transl Sci. 2014; 127:211-27. DOI: 10.1016/B978-0-12-394625-6.00008-8. View

Biasutto L, Dong L, Zoratti M, Neuzil J . Mitochondrially targeted anti-cancer agents. Mitochondrion. 2010; 10(6):670-81. DOI: 10.1016/j.mito.2010.06.004. View

Yang Y, He P, Zhang Y, Li N . Natural Products Targeting the Mitochondria in Cancers. Molecules. 2020; 26(1). PMC: 7795732. DOI: 10.3390/molecules26010092. View

Luo X, Gong X, Su L, Lin H, Yang Z, Yan X . Activatable Mitochondria-Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy. Angew Chem Int Ed Engl. 2020; 60(3):1403-1410. DOI: 10.1002/anie.202012237. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Patil S, Pandey S, Singh A, Radhakrishna M, Basu S . Hydrazide-Hydrazone Small Molecules as AIEgens: Illuminating Mitochondria in Cancer Cells. Chemistry. 2019; 25(35):8229-8235. DOI: 10.1002/chem.201901074. View

Pustylnikov S, Costabile F, Beghi S, Facciabene A . Targeting mitochondria in cancer: current concepts and immunotherapy approaches. Transl Res. 2018; 202:35-51. PMC: 6456045. DOI: 10.1016/j.trsl.2018.07.013. View

Wu J, Li J, Wang H, Liu C . Mitochondrial-targeted penetrating peptide delivery for cancer therapy. Expert Opin Drug Deliv. 2018; 15(10):951-964. DOI: 10.1080/17425247.2018.1517750. View

10.

Carew J, Huang P . Mitochondrial defects in cancer. Mol Cancer. 2003; 1:9. PMC: 149412. DOI: 10.1186/1476-4598-1-9. View

11.

Kawamura E, Maruyama M, Abe J, Sudo A, Takeda A, Takada S . Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter. Mol Ther Nucleic Acids. 2020; 20:687-698. PMC: 7210581. DOI: 10.1016/j.omtn.2020.04.004. View

12.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

13.

Ma Z, Han K, Dai X, Han H . Precisely Striking Tumors without Adjacent Normal Tissue Damage via Mitochondria-Templated Accumulation. ACS Nano. 2018; 12(6):6252-6262. DOI: 10.1021/acsnano.8b03212. View

14.

Mehra N, Jain K, Jain N . Design of multifunctional nanocarriers for delivery of anti-cancer therapy. Curr Pharm Des. 2015; 21(42):6157-64. DOI: 10.2174/1381612821666151027153106. View

15.

Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J . Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev. 2017; 117(15):10043-10120. PMC: 5611849. DOI: 10.1021/acs.chemrev.7b00042. View

16.

Bae Y, Park K . Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011; 153(3):198-205. PMC: 3272876. DOI: 10.1016/j.jconrel.2011.06.001. View

17.

Kroemer G . Mitochondria in cancer. Oncogene. 2006; 25(34):4630-2. DOI: 10.1038/sj.onc.1209589. View

18.

Dolmans D, Fukumura D, Jain R . Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3(5):380-7. DOI: 10.1038/nrc1071. View

19.

Friedman J, Nunnari J . Mitochondrial form and function. Nature. 2014; 505(7483):335-43. PMC: 4075653. DOI: 10.1038/nature12985. View

20.

Victor V, Rocha M, Banuls C, Bellod L, Hernandez-Mijares A . Mitochondrial dysfunction and targeted drugs: a focus on diabetes. Curr Pharm Des. 2011; 17(20):1986-2001. DOI: 10.2174/138161211796904722. View